- About UCB
- Our Medicines
- Join Us
One of UCB’s top priorities is to produce safe and effective therapies. Understanding how diseases such as epilepsy and rheumatoid arthritis affect people both physically and socially is key to developing transformational, personalized therapies. To gain these insights, UCB is creating a patient-centric culture that involves working closely with patients, as well as their families, caregivers and physicians.
UCB continuously seeks ways to limit the environmental impact of its day-to-day business activities, not only on its premises but also in its activities with partners.
We are committed to finding innovative ways to protect the planet and to limit our impact in terms of natural resource usage, air quality and waste generation.
UCB was ranked among the Global 100 List of the World’s Most Sustainable Companies by the Canadian organization Corporate Knights. UCB is also working globally to reduce its carbon footprint.
UCB has published its last Corporate and Societal Responsibility (CSR) report in February 2015, as part of the Annual Report 2014, available online.